Literature DB >> 7620295

Levels of plasma neuropeptide Y and other vasoactive substances during head-up tilt in normal and essential hypertensive subjects.

F Veglio1, D Schiavone, G Mengozzi, P Molino, L Chiandussi.   

Abstract

Neuropeptide Y, a potent vasoconstrictor peptide with 36 amino acid residues, is co-stored and released with catecholamines in sympathetic nerve endings. In this study responses in circulating neuropeptide Y induced by baroreceptor activation during change from the supine to the head-up position was measured in normal subjects and untreated essential hypertensives. Furthermore, the relationships with plasma catecholamines, endothelin-1, renin and serotonin were studied. No significant differences of plasma neuropeptide Y were found between normotensive and hypertensive subjects, before or after postural changes, and there was no correlation with a range of the vasoactive substances studied. Our results suggest that plasma neuropeptide Y does not increase with noradrenaline on sympathetic activation during postural stress both in normals and in hypertensive subjects. In man, measurement of plasma neuropeptide Y during head-up tilt does not provide a useful estimation of sympathetic nervous activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620295     DOI: 10.1007/BF01827465

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  17 in total

1.  Hormonal aspects of the relation of liver cirrhosis to essential hypertension.

Authors:  F Veglio; G Pinna; R Melchio; F Rabbia; M Panarelli; D Schiavone; P Mulatero; L Chiandussi
Journal:  Clin Exp Hypertens A       Date:  1992

2.  Plasma neuropeptide Y and catecholamine concentrations and urinary metanephrine excretion in patients with adrenal or ectopic phaeochromocytoma.

Authors:  P F Plouin; G Chatellier; E Grouzmann; M Azizi; T Denolle; E Comoy; P Corvol
Journal:  J Hypertens Suppl       Date:  1991-12

3.  Co-release of neuropeptide Y and catecholamines during physical exercise in man.

Authors:  J M Lundberg; A Martinsson; A Hemsén; E Theodorsson-Norheim; J Svedenhag; B Ekblom; P Hjemdahl
Journal:  Biochem Biophys Res Commun       Date:  1985-11-27       Impact factor: 3.575

4.  Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade.

Authors:  J M Lundberg; K Tatemoto
Journal:  Acta Physiol Scand       Date:  1982-12

5.  Plasma endothelin during upright tilt: relevance for orthostatic hypotension?

Authors:  H Kaufmann; E Oribe; J A Oliver
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

6.  Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Effects of ergometric exercise and acute saline loading.

Authors:  H G Predel; H Meyer-Lehnert; A Bäcker; H Stelkens; H J Kramer
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

Review 7.  Autonomic nervous system dysregulation in human hypertension.

Authors:  S Julius
Journal:  Am J Cardiol       Date:  1991-04-22       Impact factor: 2.778

8.  Neuropeptide Y-like immunoreactivity and hypertension.

Authors:  D Erlinge; R Ekman; T Thulin; L Edvinsson
Journal:  J Hypertens       Date:  1992-10       Impact factor: 4.844

9.  Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man.

Authors:  B Ullman; A Franco-Cereceda; J Hulting; J M Lundberg; A Sollevi
Journal:  J Intern Med       Date:  1990-12       Impact factor: 8.989

10.  [Differential regulation of the release of norepinephrine and neuropeptide Y].

Authors:  G Tavernier; C Damase-Michel; M A Tran; J L Montastruc; P Montastruc
Journal:  Arch Mal Coeur Vaiss       Date:  1992-08
View more
  1 in total

1.  Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients.

Authors:  G Pelosi; F Pasini; C Ottensmeier; F Pavanel; E Bresaola; A Bonetti; F Fraggetta; A Terzi; A Iannucci; G L Cetto
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.